To accurately predict the prognosis and further improve the clinical outcomes of bladder
cancer (BLCA), we leveraged large‐scale data to develop and validate a robust signature …

To the Editor: Numerous prognostic signatures to bladder cancer (BCa) have been reported,
but many of them limited to either nonmuscle-invasive (NMIBC) or muscle-invasive BCa …

Background There has been no report of prognostic signature based on immune-related
genes (IRGs). This study aimed to develop an IRG-based prognostic signature that could …

Bladder cancer (BLCA) is among the most malignant types of cancer. At present, the
prognostic tools available for this disease are insufficient. In the present study, the …

Purpose: We aimed to validate and improve prognostic signatures for high-risk urothelial
carcinoma of the bladder. Experimental Design: We evaluated microarray data from 93 …

Objectives: Bladder carcinoma is a clinical heterogeneous disease, which is with significant
variability of the prognosis and high risk of death. This revealed prominently the need to …

Traditional histopathology performed by pathologists by the naked eye is insufficient for
accurate and efficient diagnosis of bladder cancer (BCa). We collected 643 H&E‐stained …

Human bladder cancer (BCa) is the most common urogenital system malignancy. Patients
with BCa have limited treatment efficacy in clinical practice. Novel biomarkers could provide …

Purpose: We aimed to develop and validate a novel gene signature from published data and
improve the prediction of survival in muscle-invasive bladder cancer (MIBC). Methods: We …

Background Accumulating evidences demonstrated tumor microenvironment (TME) of
bladder cancer (BLCA) may play a pivotal role in modulating tumorigenesis, progression …